Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 6
Submit an article Journal homepage
176
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

T-cell subset composition and functionality in patients with Waldenström’s macroglobulinemia

Karima Amaadora Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
,
Anne Martensa Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;b Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands
,
Renate de Boerb Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands
,
Joanne Rietveldb Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands
,
Mirjam Heemskerkc Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
,
Caroline E. Ruttena Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
,
Eric Elderingb Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands;d Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands
,
Marie-José Kerstena Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;d Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-8904-3802
ORCID Icon,
Arnon P. Katera Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;d Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands
,
Josephine Vosa Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;d Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands
&
Sanne Toninoa Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;d Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The NetherlandsCorrespondence[email protected]
 show all
Pages 1469-1473 | Received 21 Dec 2021, Accepted 09 Jan 2022, Published online: 01 Feb 2022

References

  • Kaiser LM, Hunter ZR, Treon SP, et al. CXCR4 in Waldenström’s macroglobulinemia: chances and challenges. Leukemia. 2021;35(2):333–345.
  • Kristinsson SY, Koshiol J, Björkholm M, et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst. 2010;102(8):557–567.
  • Chng WJ, Schop RF, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006;108(8):2755–2763.
  • Christopoulos P, Pfeifer D, Bartholomé K, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood. 2011;117(14):3836–3846.
  • de Weerdt I, Hofland T, de Boer R, et al. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Adv. 2019;3(17):2642–2652.
  • Hofland T, Eldering E, Kater AP, et al. Engaging cytotoxic T and NK cells for immunotherapy in chronic lymphocytic leukemia. Int J Mol Sci. 2019;20(17):4315.
  • Lorentzen CL, Straten PT. CD19-chimeric antigen receptor T cells for treatment of chronic lymphocytic leukaemia and acute lymphoblastic leukaemia. Scand J Immunol. 2015;82(4):307–319.
  • Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129(26):3419–3427.
  • Martens AWJ, Janssen SR, Derks IAM, et al. CD3 × CD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. J Immunother Cancer. 2020;8(1):e000218.
  • Smith EL, Palomba ML, Park JH, et al. A systemic xenograft model of Waldenström’s macroglobulinemia demonstrates the potent anti-tumor effect of second generation CD19 directed chimeric antigen receptor modified T cells in this disease. Blood. 2014;124(21):4484.
  • Nielsen JS, Chang AR, Wick DA, et al. Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology. 2017;6(7):e1321184.
  • van Bruggen JAC, Martens AWJ, Tonino SH, et al. Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-Hodgkin lymphoma. Cancers. 2020;12(12):3837.
  • Ding W, Laplant B, Witzig TE, et al. PD-1 blockade with pembrolizumab in relapsed low grade non-Hodgkin lymphoma. Blood. 2017;130:4055.
  • Othman J, Verner E, Tam CS, et al. Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia. Haematologica. 2018;103(5):e223–e225.
  • Bannerji R, Allan JN, Arnason JE, et al. Clinical activity of REGN1979, a bispecific human, anti-CD20 × anti-CD3 antibody, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Blood. 2019;134(Suppl. 1):762.
  • Li J, Sze DMY, Brown RD, et al. Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood. 2010;115(17):3580–3588.
  • Jalali S, Price-Troska T, Paludo J, et al. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. Blood Adv. 2018;2(15):1985–1997.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.